- Todo
- Corporate News
- Events & Exhibitions
FarmaMondo to exclusively manage access to Metreleptin (Myalept®) by Amryt Pharma for patients with lipodystrophy in CIS (excluding Russia).
Amryt Pharma (www.amrytpharma.com/) has appointed FarmaMondo, the world’s leader in paid-access to unlicensed medicines, to exclusively manage the access of its innovative therapy Metreleptin (FDA/EMA approval under …
EUSA and FarmaMondo Group establishes an Emergency Managed Access Program to allow Healthcare Providers to access Siltuximab (Sylvant©) for off label treatment of acute patients of COVID-19
While the world fights through COVID19 pandemic EUSA and Papa Giovani Hospital in Italy had initiated an observational study (SISCO trial – https://clinicaltrials.gov/ct2/show/NCT04322188?term=SISCO&draw=2&rank=1) on Siltuximab …
FarmaMondo to exclusively Manage Access to Lomitapide (Lojuxta®) for the Swiss and CIS markets.
Amryt Pharma (www.amrytpharma.com/) has appointed FarmaMondo, the world’s leader in paid-access to unlicensed medicines, to exclusively manage the access of its innovative therapy Lomitapide (EMA …
FarmaMondo to exclusively manage access of Qarziba® (Dinutuximab Beta) by EUSA Pharma for patients with High Risk Neuroblastoma in LATAM and APAC regions.
FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines has been appointed by EUSA Pharma to extend its current exclusive distribution of Qarziba® …
FarmaMondo to manage access to Asparaginase (Spectrila® by Medac Pharma) for patients with acute lymphoblastic leukemia in Russia and CIS region
FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, will exclusively distribute Spectrila® via a Managed Access Program for targeted Healthcare Providers in …
FarmaMondo appointed by Amomed Pharma to exclusively Manage Access for Argipressin (Empressin®) for Russia and CIS region
FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by Amomed Pharma to exclusively distribute Empressin® via a Managed Access …
FarmaMondo establishes presence in south EU markets to provide direct to hospital service around supply of unlicensed medicines
FarmaMondo SA announces it has established operations through its Global Access business unit into several south EU markets to allow direct to hospital supply of …
FarmaMondo establishes presence in Mexico to provide direct to hospital service around supply of unlicensed medicines
FarmaMondo SA announces it has established operations in Mexico to allow direct to hospital supply of unlicensed medicines, to cover spontaneous needs and our portfolio …
FarmaMondo to manage access to Qarziba® (Dinutuximab Beta) by EUSA Pharma) for patients with High Risk Neuroblastoma in Russia and CIS region
FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by EUSA Pharma to exclusively distribute Qarziba® via a Managed Access …
FarmaMondo appointed by Rev Pharma to exclusively Manage Access for Curefini® outside the United States
FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed to exclusively distribute Curefini® dermal ointment via a Managed Access Program …
FarmaMondo establishes presence in Argentina to provide direct to hospital service around supply of unlicensed medicines
FarmaMondo SA announces it has established operations in Argentina to allow direct to hospital supply of unlicensed medicines, to cover spontaneous needs and in support …